Loading
RC148 is an experimental investigational agent whose form is not stated in the registry from RemeGen in phase 3 trials for non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
RC148 is an investigational agent whose form is not stated in the registry developed by RemeGen. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 20mg/kg, intravenous infusion, once every 2 weeks. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07416474 (RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)), in non-small-cell lung cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07416474, plans to enrol 574 participants with primary completion expected 2027-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.One arm of RC148 binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RC148" OR ABSTRACT:"RC148" OR TITLE:"RC148 plus Platinum-Based Chemotherapy" OR ABSTRACT:"RC148 plus Platinum-Based Chemotherapy" OR TITLE:"RC148 for injection" OR ABSTRACT:"RC148 for injection") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RC148, not a curated reading list.
Shares A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors, RemeGen and the tag pipeline.
Shares RemeGen and the tag pipeline.
Shares RemeGen, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares RemeGen and the tag pipeline.
Shares RemeGen and the tag pipeline.
Shares RemeGen and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.